Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis

KOÇDOR H., KOÇDOR M. A., Canda T., GÜREL D., Cehreli R., YILMAZ O., ...Daha Fazla

CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.11, sa.4, ss.243-249, 2009 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 4
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1007/s12094-009-0347-5
  • Dergi Adı: CLINICAL & TRANSLATIONAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.243-249
  • Anahtar Kelimeler: Chemoprevention, DMBA, Rosiglitazone, Fenretinide, Mammary carcinogenesis, ACTIVATED RECEPTOR-GAMMA, BREAST-CANCER, INDUCE APOPTOSIS, PPAR-GAMMA, IGF-I, RETINOIDS, PREVENTION, DIFFERENTIATION, LIGANDS, GROWTH
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and retinoic acid receptors (RAR/RXR) belong to the nuclear steroid receptor family. In vitro studies have suggested that PPAR-gamma ligands are highly effective in preventing mammary tumours and these effects are enhanced by some retinoids. However, in vivo anti-initiator and anti-promoter efficacies of this combination are not clear.